New Class of Cancer Drugs May Induce Memory Loss in Mice

Findings suggest more research on the compounds is needed.

Cancer researchers are constantly in search of more-effective and less-toxic approaches to stopping the disease, and have recently launched clinical trials testing a new class of drugs called BET inhibitors. These therapies act on a group of proteins that help regulate the expression of many genes, some of which play a role in cancer.

New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it. Published in Nature Neuroscience on August 24, the study was led by C. David Allis, Joy and Jack Fishman Professor in the Laboratory of Chromatin Biology and Epigenetics, in collaboration with Robert B. Darnell, Robert and Harriet Heilbrunn Professor and head of the Laboratory of Molecular Neuro-Oncology.

The findings will likely fuel more research into the brain effects of BET inhibitors, and could lead to the development of safer drugs that reduce the risk of potential side effects such as memory loss.

First author Erica Korb, a postdoctoral fellow in Allis’s lab, says the compound they tested in the study has the ability to cross into the brain from the bloodstream. However, this may not be the case for other drug variants tested in patients. Several companies are testing the inhibitors using unique formulations that they’ve optimized in proprietary ways–for example, by adding chemical groups to make a compound more targeted or effective–which might make it more difficult for the drug to cross the blood-brain barrier.

Many patients with hard-to-treat cancers have already received these experimental drugs. The Rockefeller scientists say their findings suggests more research is needed to determine whether the therapies can enter the brain, since that could potentially cause some unwanted side effects. “We found that if a drug blocks a BET protein throughout the body, and that drug can get into the brain, you could very well produce neurological side effects,” says Korb.

Allis, Korb and their colleagues decided to test BET inhibitors in the brain. BET proteins help regulate the process of transcribing genes into proteins, a key step in cell division. Since neurons divide less frequently than other cell types, scientists hadn’t given much consideration to the role of BET proteins in the brain, says Korb.

During the study, the researchers used a compound that was designed to thwart the activity of a specific BET protein, called Brd4. They used the original version of the drug, called Jq1, says Korb, which they knew could cross the blood-brain barrier.

The researchers added the drug to mouse neurons grown in the laboratory, then stimulated the cells in a way that mimicked the process of memory formation. Normally, when neurons receive this type of signal, they begin transcribing genes into proteins, resulting in the formation of new memories–a process that is partly regulated by Brd4. “To turn a recent experience into a long-term memory, you need to have gene transcription in response to these extracellular signals,” says Korb.

Indeed, when the researchers stimulated mouse neurons with signals that mimicked those they would normally receive in the brain, they saw massive changes in gene transcription. But when they performed this experiment after adding Jq1, they saw much less activity. “After administering a Brd4 inhibitor, we no longer saw those changes in transcription after stimuli,” says Korb.

This shows a purple stained cross section of a mouse brain.
A striking brain presence: Neurons throughout the mouse brain produce Brd4, a protein targeted by some new cancer drugs. In this cross-section of a mouse brain, Brd4-producing cells are stained red but appear purple against a blue stain that labels all cells. Credit: The Laboratory of Chromatin Biology and Epigenetics at The Rockefeller University/Nature Neuroscience.

To test how the drug affected mice’s memories, researchers placed the animals in a box with two objects they’ve never seen before, such as pieces of lego or tiny figurines. Mice typically explore anything unfamiliar, climbing and sniffing around it. After a few minutes, the researchers took the mice out of the box. One day later, they put them back in, this time with one of the objects from the day before and another, unfamiliar one.

Mice that received the placebo drug were much more interested in the new object, presumably because the one from the day before was familiar. But mice treated with Jq1 were equally interested in both objects, suggesting they didn’t remember the previous day’s experience.

Next, the researchers took their findings one step further. If Jq1 reduces molecular activity in the brain, they asked, could it help in conditions marked by too much brain activity, such as epilepsy?

Brd4 regulates a receptor protein present at the synapse, a structure where two neurons connect and transmit signals. When the researchers administered the Brd4 inhibitor, they saw decreased levels of that receptor, and neurons fired much less frequently. Next, they gave the drug to mice for a week, then added a chemical that induces seizures.

The experiment showed that mice that received Jq1 had a much lower rate of seizures than those given a placebo drug. “In the case of the epileptic brain, when there’s too much activity and neurons talking to each other, this drug could be potentially be beneficial,” says Korb. “Extending the use of these drugs into non-cancer diseases, including neurological disorders, is a largely unexplored area with much potential.” Allis adds.

About this neuropharmacology and memory research

Source: Eva Kiesler – Rockefeller University
Image Credit: The image is credited to The Laboratory of Chromatin Biology and Epigenetics at The Rockefeller University/Nature Neuroscience
Original Research: Abstract for “BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice” by Erica Korb, Margo Herre, Ilana Zucker-Scharff, Robert B Darnell and C David Allis in Nature Neuroscience. Published online August 24 2015 doi:10.1038/nn.4095


BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice

Precise regulation of transcription is crucial for the cellular mechanisms underlying memory formation. However, the link between neuronal stimulation and the proteins that directly interact with histone modifications to activate transcription in neurons remains unclear. Brd4 is a member of the bromodomain and extra-terminal domain (BET) protein family, which binds acetylated histones and is a critical regulator of transcription in many cell types, including transcription in response to external cues. Small molecule BET inhibitors are in clinical trials, yet almost nothing is known about Brd4 function in the brain. Here we show that Brd4 mediates the transcriptional regulation underlying learning and memory. The loss of Brd4 function affects critical synaptic proteins, which results in memory deficits in mice but also decreases seizure susceptibility. Thus Brd4 provides a critical link between neuronal activation and the transcriptional responses that occur during memory formation.

“BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice” by Erica Korb, Margo Herre, Ilana Zucker-Scharff, Robert B Darnell and C David Allis in Nature Neuroscience. Published online August 24 2015 doi:10.1038/nn.4095

Feel free to share this neuroscience news.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive our recent neuroscience headlines and summaries sent to your email once a day, totally free.
We hate spam and only use your email to contact you about newsletters. You can cancel your subscription any time.